10-Q: Goldenwell Biotech Faces Going Concern Amid Zero Sales Revenue

Goldenwell Biotech reported a reduced net loss and increased cash in Q2 2025, but faces significant capital needs and ongoing going concern doubts with zero product sales.

Summary

• Goldenwell Biotech, an early-stage company focused on R&D, production, and sales of health care and supplement products, reported its financial results for the quarter ended June 30, 2025.
• The company recorded a net loss of $39,596 for the six months ended June 30, 2025, a significant improvement from a net loss of $80,897 for the same period in 2024.
• Sales revenue for the six months ended June 30, 2025, was $0, a decrease from $297 in the prior year period, indicating a complete halt in product sales.
• Service revenue, however, increased to $37,500 for the six months ended June 30, 2025, from $0 in the prior year, contributing to the improved gross profit of $37,500.
• Cash balance increased to $76,507 as of June 30, 2025, from $49,404 at December 31, 2024.
• The company reported negative working capital of $(99,337) as of June 30, 2025, and an accumulated net loss of $1,399,241 since inception.
• Management has raised substantial doubt about the company's ability to continue as a going concern, citing recurring losses and dependence on raising capital.
• Disclosure controls and procedures were deemed not effective as of June 30, 2025, by management.

Sentiment

Score: 2

Explanation: The company is in a highly precarious financial position, marked by zero product sales, a going concern warning, significant capital requirements without secured funding, and ineffective disclosure controls. While net loss decreased and cash increased, these positives are overshadowed by fundamental operational and financial instability.

Positives

• Net loss significantly decreased to $39,596 for the six months ended June 30, 2025, from $80,897 in the prior year period.
• Cash balance increased to $76,507 as of June 30, 2025, from $49,404 at December 31, 2024.
• The company generated $37,500 in service revenue for the six months ended June 30, 2025, which was not present in the prior year period.
• Net cash from operating activities was positive $27,104 for the six months ended June 30, 2025, compared to a negative $(76,761) in the prior year, primarily driven by unearned service revenue.

Negatives

• Sales revenue from products was $0 for the six months ended June 30, 2025, indicating a complete cessation of product sales.
• The company has an accumulated net loss of $1,399,241 since its inception, raising substantial doubt about its ability to continue as a going concern.
• Working capital was negative $(99,337) as of June 30, 2025, highlighting liquidity challenges.
• Management concluded that disclosure controls and procedures were not effective as of June 30, 2025.
• The company requires approximately $5,000,000 to construct manufacturing facilities and train its workforce, with no guaranteed funding.

Risks

• The company's ability to continue as a going concern is dependent on generating revenues and obtaining capital from third parties, with no assurance of success.
• Inability to raise additional capital through debt or equity offerings could lead to the failure of the business plan.
• Future equity financing would result in dilution for existing shareholders.
• The company is in the development stage and has little operations or revenues to date.
• Reliance on related party transactions for inventory purchases and long-term loans introduces potential conflicts of interest and financial dependence.
• Actual results may differ materially from forward-looking statements due to factors such as product demand, market acceptance, competition, pricing, climate change, pandemics, political changes, and development difficulties.
• Ineffective disclosure controls and procedures pose a risk to the accuracy and timeliness of financial reporting.

Future Outlook

The company plans to increase sales of its products and believes it can satisfy cash requirements through December 31, 2024, from its current cash balance. However, it needs approximately $5,000,000 to construct manufacturing facilities and train its workforce, which is estimated to take one year. Additional funding is expected to come from equity financing through the sale of common stock, but there is no guarantee of success in raising this capital.

Management Comments

• "The Company has sustained an accumulated net loss of $1,399,241 since its inception. These factors, among others, raise substantial doubt about the ability of the Company to continue as a going concern for a reasonable period of time."
• "The Companys continuation as a going concern is dependent upon, among other things, its ability to generate revenues and its ability to obtain capital from third parties. No assurance can be given that the Company will be successful in these efforts."
• "We estimate that we need approximately $5,000,000 to complete such activities [constructing manufacturing facilities and training workforce] and that it would take approximately one year to complete such activities."
• "Additional funding will likely come from equity financing from the sale of our common stock, if we are able to sell such stock. If we are successful in completing an equity financing, existing shareholders will experience dilution of their interest in our Company."
• "We do not have any financing arranged and we cannot provide investors with any assurance that we will be able to raise sufficient funding from the sale of our common stock to fund our activities. In the absence of such financing, our business will fail."

Industry Context

NA

Corporate Governance

Related Party Transactions

• On June 7, 2021, the company purchased inventory of $103,125 from Australian Trefoil Heath Technology, a company owned by Li, Yang, the Treasurer of Goldenwell Biotech.
• As of June 30, 2025, the company had long-term loans totaling $95,599 from Shuang Liu, the Chief Executive Officer.

Stakeholder Impact

• Shareholders face a high risk of significant dilution if the company successfully raises capital through equity offerings.
• Shareholders also face a substantial risk of losing their investment due to the explicit going concern warning and the potential failure of the business if capital cannot be raised.
• Creditors (including the CEO as a lender) face elevated risk due to the company's financial distress and going concern status.
• Potential employees for manufacturing facilities face uncertainty regarding job creation given the contingent nature of funding and facility construction.

Next Steps

• Increase sales of health care and supplement products.
• Construct manufacturing facilities, including locating a site, installing a workshop, and setting up equipment.
• Train the workforce for manufacturing operations.
• Raise approximately $5,000,000 through debt or equity offerings to fund manufacturing and operations.

Key Dates

Recommendation

Goldenwell Biotech presents an extremely high-risk investment profile. The explicit 'going concern' warning, coupled with zero sales revenue from its core product business, negative working capital, and a substantial accumulated deficit, indicates severe financial distress. While cash increased and net loss decreased, these are overshadowed by the fundamental lack of a viable, revenue-generating business model and the critical need for $5 million in capital with no assured funding. The ineffective disclosure controls further compound the risk. Investors face a high probability of significant capital loss and dilution if the company manages to secure financing. The current operational and financial state suggests a strong likelihood of business failure.

Keywords

Goldenwell Biotech, 10-Q, Q2 2025, biotech, health supplements, nutraceuticals, going concern, capital raise, financial results, disclosure controls, related party transactions